Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Although all KRas (protein that in humans is encoded by the KRas gene) point mutants are considered to have a similar prognostic capacity, their transformation and tumorigenic capacities vary widely. We compared the metastatic efficiency of KRas G12V (Kirsten rat sarcoma viral oncogene homolog with valine mutation at codon 12) and KRas G13D (Kirsten rat sarcoma viral oncogene homolog with aspartic mutation at codon 13) oncogenes in an orthotopic colorectal cancer (CRC) model. Following subcutaneous preconditioning, recombinant clones of the SW48 CRC cell line [Kras wild‐type (Kras WT)] expressing the KRas G12V or KRas G13D allele were micro‐injected in the mouse cecum. The percentage of animals developing lymph node metastasis was higher in KRas G12V than in KRas G13D mice. Microscopic, macroscopic, and visible lymphatic foci were 1.5‐ to 3.0‐fold larger in KRas G12V than in KRas G13D mice ( P < 0.05). In the lung, only microfoci were developed in both groups. KRas G12V primary tumors had lower apoptosis (7.0 ±1.2 vs . 7.4 ± 1.0 per field, P = 0.02), higher tumor budding at the invasion front (1.2 ± 0.2 vs . 0.6 ± 0.1, P = 0.04), and a higher percentage of C‐X‐C chemokine receptor type 4 (CXCR4)‐overexpressing intravasated tumor emboli (49.8 ± 9.4% vs . 12.8 ± 4.4%, P < 0.001) than KRas G13D tumors. KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine‐1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression. The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing (his oncogene.—Alamo, P., Gallardo, A., Di Nicolantonio, F., Pavón, M. A., Casanova, I., Trias, M., Mangues, M. A., Lopez‐Pousa, A., Villaverde, A., Vázquez, E., Bardelli, A., Céspedes, M. V., Mangues, R. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB J . 29, 464‐476 (2015). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748 · cited 2×
“Moreover, the higher agressiveness observed in KRas G12V mice is consistent with the shorter overall survival observed in CRC patients with KRas G12V mutation compared to other Kras mutations, in the RASCAL study (3).”
Peeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232 · cited 1×
“However, more recent clinical data are contradictory (51).”
Minami, T., Jiang, S., Schadler, K., Suehiro, J.-I., Osawa, T., Oike, Y., Miura, M., Naito, M., Kodama, T., & Ryeom, S. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.021 · Cited by 111
Cited by
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0818 · Cited by 136
Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021) · Cells · doi:10.3390/cells10030667 · Cited by 58
Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab
Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., Koopmansch, B., MacKay, G. M., Chiavarina, B., Costanza, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.012 · Cited by 38
Metadata
- Authors
- Alamo, P., Gallardo, A., Di Nicolantonio, F., Pavón, M. A., Casanova, I., Trias, M., Mangues, M. A., Lopez‐Pousa, A., Villaverde, A., Vázquez, E., Bardelli, A., Céspedes, M. V., & Mangues, R.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2014-10-30
- Volume
- 29
- Issue
- 2
- Pages
- 464-476
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2012424523
- Cited by
- 50
- References
- 3
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. https://app.cochat.ai/papers/10.1096/fj.14-262303
- The paper
- Alamo, P., Gallardo, A., Di Nicolantonio, F., Pavón, M. A., Casanova, I., Trias, M., Mangues, M. A., Lopez‐Pousa, A., Villaverde, A., Vázquez, E., Bardelli, A., Céspedes, M. V., & Mangues, R. (2015). Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. The FASEB Journal. https://doi.org/10.1096/fj.14-262303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.